Early-Stage Breast Cancer: TAILORx and Chemotherapy Decision-Making

Dr. Allison DiPasquale invites Dr. Sonya Reid to discuss the clinical impact of the landmark TAILORx trial on the management of early-stage HR-positive, HER2-negative, node-negative breast cancer. Dr. Reid reviews the pivotal findings demonstrating that many patients with intermediate recurrence scores can safely avoid adjuvant chemotherapy without compromising outcomes, highlighting how these data have transformed contemporary treatment decision-making. She explains that genomic recurrence scores provide an objective measure that complements traditional clinicopathologic factors, allowing clinicians to better identify patients who are unlikely to benefit from chemotherapy while supporting more personalized treatment recommendations. Dr. DiPasquale reflects on how these findings have improved patient confidence in treatment decisions by helping avoid unnecessary therapy while ensuring appropriate treatment for higher-risk disease. Together, the faculty emphasize that integrating genomic testing with clinical assessment has advanced individualized care in early-stage breast cancer, reducing overtreatment while maintaining evidence-based management and shared decision-making.